Emerging cancer-targeted therapies

被引：5

作者：

Arceci, RJ

Cripe, TP

机构：

[1] Johns Hopkins Oncol Ctr, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA

[2] Johns Hopkins Oncol Ctr, Sidney Kimmel Comprehens Canc Ctr, Dept Pediat, Baltimore, MD 21231 USA

[3] Univ Cincinnati, Div Hematol Oncol, Cincinnati Childrens Hosp, Ctr Med, Cincinnati, OH USA

来源：

PEDIATRIC CLINICS OF NORTH AMERICA | 2002年 / 49卷 / 06期

关键词：

D O I：

10.1016/S0031-3955(02)00096-2

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

There is reason to believe that the unfolding revolution in molecular biology and translational research will allow selective targeting of tumor cells, and radically change the way general practitioners and pediatric oncologists treat and follow children with cancer. This article highlights some of the most promising approaches being tested in the field. By learning about the underlying biology, the remaining hurdles, the projected timeline, and the possible impact of new therapies on the practice of pediatric oncology, health care professionals and patients should be better prepared for the future of pediatric oncology.

引用

页码：1339 / +

页数：32

共 219 条

[1]

Adachi Y, 2001, CANCER RES, V61, P7882

[2] Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar) [J].